

Esquistosomiasis

Referencias

- 1 Ross AGP, Bartley PB, Sleigh AC, Olds GR, Li Y, Williams GM, McManus DP. Schistosomiasis. *N Eng J Med* 2002;346:1212-9.
- 2 Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. *Lancet* 2006;368:1106-18.
- 3 Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. *Lancet Infect Dis* 2006;6:411-25.
- 4 King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helminthic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. *Lancet* 2005;365:561-9.
- 5 King CH, Dangerfield-Cha M. The unacknowledged impact of chronic schistosomiasis. *Chronic Illness* 2008;4:65-79.
- 6 Mas-Coma S, Valero MA, Bargues MD. Climate change effects on trematodiasis, with emphasis on zoonotic fascioliasis and schistosomiasis. *Vet Parasitol* 2009;163:264-80.
- 7 Leshem E, Meltzer E, Marva E, Schwartz E. Travel-related schistosomiasis acquired in Laos. *Emerg Infect Dis* 2009;15:1823-6.
- 8 Ross AG, Vickers D, Olds GR, Shah SM, McManus DP. Katayama syndrome. *Lancet Infect Dis* 2007;7:218-24.
- 9 Wynn TA, Thompson RW, Cheever AW, Mentink-Kane MM. Immunopathogenesis of schistosomiasis. *Immunol Rev* 2004;201:156-67.
- 10 Burke ML, Jones MK, Gobert GN, Li YS, Ellis MK, McManus DP. Immunopathogenesis of human schistosomiasis. *Parasite Immunol* 2009;31:163-76.
- 11 Carod-Artal FJ. Neurological complications of *Schistosoma* infection. *Trans R Soc Trop Med Hyg* 2008;102:107-16.
- 12 Ferrari TC. Involvement of the central nervous system in the schistosomiasis. *Mem Inst Oswaldo Cruz* 2004;99:59-62.
- 13 McManus DP, Gray DJ, Li YS, Feng Z, Williams GM, Stewart D, et al. Schistosomiasis in the Peoples' Republic of China: the era of the Three Gorges Dam. *Clinic Microbiol Rev* 2010;23:442-66.
- 14 Katz N, Chaves A, Pellegrino J. A simple device for quantitative stool thick-smear technique for schistosomiasis mansoni. *Rev Inst Med Trop Sao Paulo* 1972;14:397-400.
- 15 Oliveira LM, Santos HL, Gonçalves MM, Barreto MG, Peralta JM. Evaluation of polymerase chain reaction as an additional tool for the diagnosis of low-intensity *Schistosoma mansoni* infection. *Diagn Microbiol Infect Dis* 2010;68:416-21.
- 16 Wichmann D, Panning M, Quack T, Kramme S, Burchard GD, Grevelding C, Drosten C. Diagnosing schistosomiasis by detection of cell-free parasite DNA in human plasma. *PLoS Negl Trop Dis* 2009;3:e422.
- 17 Gomes LI, Dos Santos Marques LH, Enk MJ, de Oliveira MC, Coelho PM, Rabello A. Development and evaluation of a sensitive PCR-ELISA system for detection of *Schistosoma* infection in feces. *PLoS Negl Trop Dis* 2010;4:e664.
- 18 Ellis MK, Li Y, Hou X, Chen H, McManus DP. sTNFR-II and sICAM-1 are associated with acute disease and hepatic inflammation in schistosomiasis japonica. *Int J Parasitol* 2008;38:717-23.
- 19 Bergquist R, Johansen MV, Utzinger J. Diagnostic dilemmas in helminthology: what tools to use and when? *Trends Parasitol* 2009;25:151-6.
- 20 Chand MA, Chiodini PL, Doenhoff MJ. Development of a new assay for the diagnosis of schistosomiasis, using cercarial antigens. *Trans R Soc Trop Med Hyg* 2010;104:255-8.
- 21 Stothard JR, Sousa-Figueiredo JC, Standley C, Van Dam GJ, Knopp S, Utzinger J, et al. An evaluation of urine-CCA strip test and fingerprick blood SEA-ELISA for detection of urinary schistosomiasis in schoolchildren in Zanzibar. *Acta Trop* 2009;111:64-70.
- 22 Doenhoff MJ, Cioli D, Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. *Curr Opin Infect Dis* 2008;21:659-67.
- 23 Cioli D, Pica-Mattoccia L. Praziquantel. *Parasitol Res* 2003;90:S3-S9.
- 24 Hou XY, McManus DP, Gray DJ, Balen J, Luo XS, He YK, et al. A randomized, double-blind, placebo-controlled trial of safety and efficacy of combined praziquantel and artemether treatment for acute schistosomiasis japonica in China. *Bull World Health Organ* 2008;86:788-95.
- 25 Li Y, Sleigh AC, Williams GM, Ross AG, Forsyth SJ, Tanner M, McManus DP. Measuring exposure to *Schistosoma japonicum* in China. III. Activity diaries, snail and human infection, transmission ecology and options for control. *Acta Trop* 2000;75:279-89.
- 26 Sayed AA, Simeonov A, Thomas CJ, Inglese J, Austin CP, Williams DL. Identification of oxadiazoles as new drug leads for the control of schistosomiasis *Nat Med* 2008;14:407-12.
- 27 Keiser J, N'Guessan NA, Adoubryn KD, Silué KD, Vounatsou P, Hatz C, et al. Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, and praziquantel against *Schistosoma haematobium*: randomized, exploratory open-label trial. *Clin Infect Dis* 2010;50:1205-13.

- 28 Utzinger J, Xiao SH, Tanner M, Keiser J. Artemisinins for schistosomiasis and beyond. *Curr Opin Investig Drugs* 2007;8:105-16.
- 29 Xiao SH. Development of antischistosomal drugs in China, with particular consideration to praziquantel and the artemesinins. *Acta Trop* 2005;96:153-67.
- 30 Obonyo CO, Muok EM, Mwinzi PN. Efficacy of artesunate with sulfalene plus pyrimethamine versus praziquantel for treatment of *Schistosoma mansoni* in Kenyan children: an open-label randomised controlled trial. *Lancet Infect Dis* 2010;10:603-11.
- 31 Utzinger J, Tanner M, Keiser J. ACTs for schistosomiasis: do they act? *Lancet Infect Dis* 2010;10:579-81.